AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
—Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated…
—Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated…
– Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related…
– Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related…